Greenwood Capital Associates LLC Sells 23,534 Shares of Danaher Co. (NYSE:DHR)

Greenwood Capital Associates LLC decreased its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 78.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,397 shares of the conglomerate's stock after selling 23,534 shares during the period. Greenwood Capital Associates LLC's holdings in Danaher were worth $1,311,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in DHR. Spinnaker Trust boosted its holdings in shares of Danaher by 1.2% in the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate's stock valued at $988,000 after purchasing an additional 50 shares in the last quarter. Fortis Capital Advisors LLC boosted its stake in Danaher by 1.3% in the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after buying an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its position in Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after acquiring an additional 50 shares during the last quarter. Coastal Bridge Advisors LLC raised its stake in Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares in the last quarter. Finally, Perennial Investment Advisors LLC lifted its holdings in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after acquiring an additional 51 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 2.1%

NYSE DHR traded down $4.30 during mid-day trading on Friday, reaching $200.80. 2,174,860 shares of the stock were exchanged, compared to its average volume of 3,491,010. The stock has a market cap of $143.71 billion, a P/E ratio of 38.03, a P/E/G ratio of 2.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a one year low of $171.00 and a one year high of $281.70. The stock has a 50 day simple moving average of $192.27 and a 200-day simple moving average of $211.44.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on DHR shares. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Citigroup reaffirmed a "buy" rating on shares of Danaher in a research note on Monday, April 7th. HSBC dropped their price target on Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Royal Bank of Canada restated an "outperform" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Finally, TD Cowen increased their target price on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $248.17.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.